Katalip

Fenofibrate, the active ingredient in Katalip, is a fibrate presented as an oral formulation for oral use. It reduces elevated triglyceride and cholesterol concentrations in adults with hyperlipidemia, especially those with high triglycerides, mixed dyslipidemia, or as adjunct therapy for primary hypercholesterolemia. The drug works by activating peroxisome proliferator‑activated receptor alpha (PPARα) to enhance lipid metabolism.

GNH USA supplies Katalip as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU pharmaceutical standards and is distributed globally.

Fenofibrate is used to treat lipid disorders by targeting elevated triglyceride and cholesterol levels.

Hypertriglyceridemia: reduces serum triglyceride concentrations. Mixed dyslipidemia: lowers triglycerides and modestly raises HDL‑cholesterol. Primary hypercholesterolemia (adjunct): complements statin therapy to improve overall lipid profile.

Fenofibrate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Gastrointestinal discomfort such as nausea or abdominal pain. - Headache. - Muscle aches or mild myalgia. - Elevated liver enzymes. - Dizziness. - Skin rash.

Serious or Rare Side Effects: - Rhabdomyolysis leading to renal failure. - Severe liver injury or hepatitis. - Gallstone formation. - Acute pancreatitis. - Anaphylactic or severe allergic reactions. - Blood dyscrasias such as neutropenia.

Before initiating therapy, consider the following safety measures.

Renal impairment: monitor renal function and adjust therapy as needed. Hepatic disease: avoid use in patients with severe liver dysfunction. Pregnancy: contraindicated (Category X) – do not use during pregnancy. Elderly patients: observe closely for signs of muscle toxicity. Concomitant statin therapy: assess risk of myopathy and adjust dosing. Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Fenofibrate can interact with several medicines, requiring caution.

Major Interactions (Avoid): - Cyclosporine: increased fenofibrate concentrations. - Gemfibrozil: heightened risk of rhabdomyolysis. - Anticoagulants (warfarin): potentiated anticoagulant effect.

Moderate Interactions (Monitor Closely): - Statins: monitor for muscle toxicity. - Thiazide diuretics: may increase serum creatinine.